Pfizer: A Smart Investment Move?

Pfizer's stock is a popular choice for investors, but is it a smart investment right now?

Pfizer gained renewed interest during the pandemic due to its COVID-19 vaccine, developed with German biotech company BioNTech. The company has continued to make headlines with its recent advancements, including the approval of its gene therapy for hemophilia B, and positive results for its respiratory syncytial virus vaccine.

However, sales growth has been unpredictable, with only two years of positive annual growth in the past nine years. Sales are expected to drop by 5% in 2020, and revenue from its COVID products is declining.

So, while Pfizer's stock is included in dozens of health care and pharmaceutical index funds and ETFs, and the company has a strong dividend that has steadily increased, investors need to consider the company's future potential and how it fits into their portfolio before buying.

Pfizer's stock price and market performance

Pfizer's stock price has been volatile in recent years, with the company's shares trading in a relatively tight range over the past year. As of June 2024, the stock is hovering around $27 per share, which is near an 11-year low.

Pfizer gained renewed interest during the COVID-19 pandemic due to its development of a vaccine in partnership with BioNTech. The vaccine news caused a spike in the company's stock price, but it has since declined as revenue from COVID-19 products continues to fall.

Pfizer has a market capitalisation of $224 billion and, in 2019, the company had eight drugs that each generated over $1 billion in sales. The company's top three drugs, including a pneumonia vaccine, a cancer drug, and a blood thinner, accounted for 29% of its total revenue.

However, sales growth has been inconsistent, with only two years of positive annual growth in the past nine years. Sales declined by 4% in 2019, and despite the vaccine, sales are expected to drop by another 5% in 2020.

Pfizer's stock is included in numerous health care, pharmaceutical, and dividend index funds and ETFs. The company has a strong dividend that has steadily increased, and its stock price was less volatile than most of its competitors in 2020.

When considering investing in Pfizer, it is important to look beyond the headlines and evaluate the company's future potential, its fit within your portfolio, and your own financial situation.

Pfizer's vaccine development and distribution

Pfizer has a rich history in vaccine research and development, having played a pivotal role in eliminating or nearly eliminating deadly infectious diseases such as smallpox and polio globally. The company has designed novel vaccines based on new delivery systems and technologies, including vaccines to prevent bacterial infections caused by S. pneumoniae and N. meningitidis.

Pfizer's vaccine development efforts are focused on three key areas: addressing high-impact infectious diseases, expanding the benefits of maternal immunisation, and investigating cancer vaccines. The company is committed to bringing the benefits of vaccines to every age group, from maternal and infant populations to seniors.

In terms of distribution, Pfizer operates a sophisticated supply chain system with over 35 Pfizer-owned sites and over 300 suppliers globally. For the COVID-19 vaccine, Pfizer activated its extensive US and European manufacturing networks, preparing thousands of skilled workers in multiple states and localities to produce the vaccine. The company currently has the capacity to produce 4 billion doses annually, pending demand.

Pfizer's distribution approach for the COVID-19 vaccine involves shipping frozen vials directly to the point of vaccination using road and air transportation. The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and continuous temperature monitoring.

To maintain vaccine integrity during distribution, Pfizer has developed packaging and storage innovations, including temperature-controlled thermal shippers that utilise dry ice to maintain recommended temperature conditions for up to 10 days unopened. These shippers are strategically transported by air to major hubs and then by ground transport to dosing locations.

Pfizer's experience and capabilities in supply chain and cold chain management have been crucial in the successful development and distribution of its vaccines, including the COVID-19 vaccine.

Pfizer's financial health and sales performance

However, Pfizer reported a drop in revenue for the full year 2023, with revenues declining 42% from the previous year due primarily to reduced sales of COVID-19 products. The company's 2023 revenues stood at $58.5 billion, down from $100.33 billion in 2022. The decline was attributed to a 41% operational decrease, a 1% negative impact from foreign exchange rates, and reduced global sales of its COVID-19 vaccine and antiviral treatment.

Despite the overall decline, Pfizer's financials excluding COVID-19 products showed 7% operational growth in 2023. The company's first-quarter sales in 2024 were boosted by a one-time benefit from the COVID-19 drug Paxlovid, with revenue from the firm's cardiomyopathy treatment Vyndaqel also exceeding expectations. Pfizer has reaffirmed its full-year 2024 guidance and expects revenues to range between $58.5 billion and $61.5 billion, with an adjusted diluted EPS forecast of $2.05 to $2.25.

In terms of financial health, Pfizer's debt has increased over the past year, but its cash flow coverage appears adequate to meet its obligations. The company's current ratio, which measures its ability to pay short-term obligations, is at a reasonable level of 1.54x. Pfizer's debt-to-equity ratio is relatively high at 77%, but this is not uncommon for large companies, and the company's interest payments are comfortably covered by its earnings. Overall, Pfizer's financial health appears solid, but investors should continue to monitor the company's performance and outlook.

Pfizer's investment potential and portfolio fit

Pfizer's stock is a tempting investment opportunity, especially with the company regularly making headlines with its innovations in healthcare. However, there are several factors to consider when assessing the company's investment potential and portfolio fit.

Firstly, it is important to analyse Pfizer's future potential. While the company has been in the limelight recently due to its COVID-19 vaccine, investors need to look beyond the headlines. Pfizer's potential success may already be reflected in the current stock price, and it is crucial to remember that institutional investors have more resources to uncover information that moves stock prices. Therefore, retail investors should avoid investing solely based on past performance or the current price.

Secondly, consider how Pfizer stock fits into your portfolio. Pfizer is considered a large-cap value company, indicating that it may not experience the rapid growth typical of newer tech companies. However, Pfizer offers a strong dividend that has been steadily increasing, and its stock price has been less volatile compared to its competitors. Thus, Pfizer may be a good fit for investors seeking less volatile, income-producing value stocks.

Additionally, Pfizer has a diverse range of products, with eight drugs each generating over $1 billion in sales in 2019. The company's top three drugs, including a pneumonia vaccine, a cancer drug, and a blood thinner, accounted for 29% of its total revenue. However, sales growth has been unpredictable, with only two years of positive annual growth in the past nine years. Sales declined by 4% in 2019, and despite the vaccine, a further drop of 5% is expected in 2020.

When assessing Pfizer's investment potential, it is also essential to examine the broader market and industry trends. Pfizer's stock is included in numerous health care, pharmaceutical, and dividend index funds and ETFs, reflecting its position as one of the world's largest pharmaceutical companies.

Finally, investors should decide how much to invest in Pfizer stock by evaluating their financial situation and ensuring they have adequate emergency cash savings. Investing in Pfizer should be considered for those with a long-term investment horizon, as financial advisors generally recommend a minimum of five years for any stock market investment.

In summary, while Pfizer has been in the spotlight due to its COVID-19 vaccine, investors need to look beyond the headlines and carefully consider the company's future potential, its fit within their portfolio, and their own financial situation before making an investment decision.

Pfizer's stock purchase options

Pfizer (PFE) stock is a popular choice for investors, but is it a smart choice? Here are some things to consider before investing in Pfizer stock.

Pfizer's Performance and Future Potential

Pfizer has been in the limelight recently due to its COVID-19 vaccine, which was developed in partnership with BioNTech. The company has also been making headlines for its innovations in healthcare, with new drug approvals and encouraging results from ongoing studies. However, investors should be cautious about investing based solely on headlines or past performance. It's important to consider Pfizer's future potential and how it fits into your portfolio.

Pfizer's Stock Price and Financial Performance

Pfizer's stock price has experienced ups and downs over the past year, trading in the $25-$42 range. The company's revenue and sales growth have been unpredictable, with only two years of positive annual growth in the past nine years. Sales declined by 4% in 2019, and despite the success of the COVID-19 vaccine, sales are expected to drop further in 2020.

Analyst Recommendations and Ratings

Analysts have given mixed recommendations for Pfizer stock. While some analysts have highlighted the company's "massive" upside, others have advised against buying the stock at the moment. It's rated as a "Strong Buy" or "Buy" by some sources, while others suggest waiting for a better entry point as the stock is not forming a clear chart pattern.

How to Buy Pfizer Stock

If you decide to invest in Pfizer, you can purchase the stock through a brokerage account or Pfizer's direct stock purchase plan. When buying through a brokerage, you'll need to add funds to your account and search for "PFE" within the platform. It's important to consider your financial situation, perform due diligence, and determine how much you're comfortable investing.

Pfizer's Place in Your Portfolio

Before investing in Pfizer, evaluate how it fits into your existing portfolio. Consider whether it adds too much weight to a particular sector or industry, creates an imbalance between value and growth stocks, or puts too much weight on equities. Pfizer is considered a large-cap value company, which suggests steadier growth compared to newer tech companies. The company offers a strong and steadily increasing dividend, and its stock price has been less volatile than competitors.

In conclusion, while Pfizer has been in the spotlight recently due to its COVID-19 vaccine, investors should carefully consider the company's future potential, financial performance, and how it fits into their portfolio before making a decision.

Frequently asked questions